CVS expands HealthHub concept to new markets

After introducing its new HealthHub concept store in Texas, CVS Health is spreading the store model to Boston, Dallas/Fort Worth, Maryland, North Carolina, Ohio and Virginia, the company announced. The HealthHub concept offers consumers more healthcare services, wellness products and personalized care.

Earlier this year, CVS announced it would bring the concept to 1,500 stores across the U.S., with 50 locations in Atlanta, Houston, Philadelphia, southern New Jersey, and Tampa. CVS operates nearly 10,000 retail locations and 1,100 walk-in clinics.

“Our customers tell us they want local access to convenient, personalized and integrated health care support and services,” Kevin Hourican, executive vice president of CVS Health and president of CVS Pharmacy, said in a statement. “HealthHUB delivers on that ask and we can’t wait for customers in these communities to benefit from a better health care experience.”

The company also plans to add HealthHub locations in cities in Florida, as well as a limited expansion in Hartford, New York City, and Washington, D.C.

“Our customers love the new format,” Hourican said. “And by creating a unique health care experience that meets consumers where they are and helps them achieve their best health at a lower cost, we’ve set the stage for our company to compete and win in an industry that is rapidly transforming.”

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.